Description  Claims  Drawing  Cited references 

US61929680   [0001] 
WO2011130689A   [0011] 

Applied Microbiology   [0028] 
The emerging functions of histone demethylases   [0107] 
Involvement of poly(ADP-ribose) polymerase-1 and XRCC1/DNA ligase III in an alternative route for DNA double-strand breaks rejoining   [0107] 
Involvement of polynucleotide kinase in a poly(ADP-ribose) polymerase-1-dependent DNA double-strand breaks rejoining pathway   [0107] 
A decade of exploring the cancer epigenome - biological and translational implications   [0107] 
Regulation of chromatin structure by poly(ADP-ribosyl)ation   [0107] 
Alternative-NHEJ is a mechanistically distinct pathway of mammalian chromosome break repair   [0107] 
Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia   [0107] 
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase   [0107] 
An FLT3 gene-expression signature predicts clinical outcome in normal karyotype AML   [0107] 
Epigenetics: poly(ADP-ribosyl)ation of PARP-1 regulates genomic methylation patterns   [0107] 
Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)   [0107] 
ADP-ribose)n participates in DNA excision repair   [0107] 
Human induced pluripotent cells resemble embryonic stem cells demonstrating enhanced levels of DNA repair and efficacy of nonhomologous end-joining   [0107] 
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy   [0107] 
Ku regulates the non-homologous end joining pathway choice of DNA double-strand break repair in human somatic cells   [0107] 
Microsatellite instability induced mutations in DNA repair genes CtIP and MRE11 confer hypersensitivity to poly (ADP-ribose) polymerase inhibitors in myeloid malignancies   [0107] 
Increased error-prone non homologous DNA end-joining--a proposed mechanism of chromosomal instability in Bloom's syndrome   [0107] 
Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes   [0107] 
PARP inhibitors stumble in breast cancer   [0107] 
Ataxia telangiectasia mutated (ATM) signaling network is modulated by a novel poly(ADP-ribose)-dependent pathway in the early response to DNA-damaging agents   [0107] 
The diverse biological roles of mammalian PARPS, a small but powerful family of poly-ADP-ribose polymerases   [0107] 
The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings   [0107] 
Poly(ADP-ribose) polymerase (PARP-1) in homologous recombination and as a target for cancer therapy   [0107] 
DNA repair pathways as targets for cancer therapy   [0107] 
Triple-negative breast cancer: role of specific chemotherapy agents   [0107] 
Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies   [0107] 
DNA methylation and cancer   [0107] 
Cellular differentiation, cytidine analogs and DNA methylation   [0107] 
Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer   [0107] 
Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study   [0107] 
CHFR protein regulates mitotic checkpoint by targeting PARP-1 protein for ubiquitination and degradation   [0107] 
DNA double-strand breaks: signaling, repair and the cancer connection   [0107] 
ATM, a central controller of cellular responses to DNA damage   [0107] 
Chromatin modifications and their function   [0107] 
Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly (ADP-ribose) polymerase inhibition   [0107] 
Effects of chromatin decondensation on alternative NHEJ   [0107] 
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors   [0107] 
Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib   [0107] 
Radiosensitization by the poly(ADP-ribose) polymerase inhibitor 4-amino-1,8-naphthalimide is specific of the S phase of the cell cycle and involves arrest of DNA synthesis   [0107] 
Oxidative damage targets complexes containing DNA methyltransferases, SIRT1, and polycomb members to promoter CpG Islands   [0107] 
Targeting abnormal DNA double strand break repair in cancer   [0107] 
Transfection and homologous recombination involving single-stranded DNA substrates in mammalian cells and nuclear extracts   [0107] 
HDAC inhibitors: roles of DNA damage and repair   [0107] 
PARP inhibition: PARP1 and beyond   [0107] 
Spontaneous homologous recombination is induced by collapsed replication forks that are caused by endogenous DNA single-strand breaks   [0107] 
Internal tandem duplication of FLT3 (FLT3/ITD) induces increased ROS production, DNA damage, and misrepair: implications for poor prognosis in AML   [0107] 
Up-regulation of WRN and DNA ligase IIIalpha in chronic myeloid leukemia: consequences for the repair of DNA double-strand breaks   [0107] 
Overlapping but distinct patterns of histone acetylation by the human coactivators p300 and PCAF within nucleosomal substrates   [0107] 
BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency   [0107] 
Targeting abnormal DNA repair in therapy-resistant breast cancers   [0107] 
Targeting abnormal DNA double-strand break repair in tyrosine kinase inhibitor-resistant chronic myeloid leukemias   [0107] 
Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells   [0107] 
Cancer susceptibility and the functions of BRCA1 and BRCA2   [0107] 
Poly(ADP-ribose) polymerase and XPF-ERCC1 participate in distinct pathways for the repair of topoisomerase I-induced DNA damage in mammalian cells   [0107]